New chemistry specialist
capital and assets of Selact in a move that bolsters its
capabilities in chemical synthesis and contract research.
The acquisition will allow Kiadis to offer clients services in isolating bioactive molecules from complex mixtures, as well as carry out advanced chemical synthesis and lead optimisation in house. Selact, which has focused on building up a position in the area of difficult to synthesize molecules, chiral synthesis, chiral catalysis and analytical support will operate as a wholly owned subsidiary of Kiadis.
The combined company has additional resources and sufficient cash reserves to continue to progress and expand on Kiadis high-resolution screening.
Gerard Dijkstra, Kiadis' CEO, said the acquisition would allow the company's clients "to access first class molecular chemistry, a sine qua non for drug discovery and development."
Financial terms of the acquisition have not been disclosed.
